Positive in Ames; negative in in vitro human lymphocyte micronucleus and in vivo mouse bone marrow micronucleus assays
“Fexinidazole was mutagenic (positive in strains TA98, TA100, and TA1535 in the presence and absence of S9 and TA1537, and TA102 in the presence of S9) but was negative in the in vitro micronucleus assays in cultured human peripheral blood lymphocytes up to 180 µg/mL (+/-S9), and the in vivo micronucleus assay in the bone marrow of treated mice (2 oral doses up to 2000 mg/kg).”
✓ VerifiedFDA multi-discipline review, p. 57Source ↗
Carcinogenicity
Not conducted; related nitroimidazoles are carcinogenic in rodents
“Carcinogenicity studies are not indicated for fexinidazole and were not conducted. However, structurally related compounds such as metronidazole have exhibited carcinogenic potential in lifetime animal studies.”
✓ VerifiedFDA multi-discipline review, p. 74Source ↗
Reproductive & developmental
Rat EFD: delayed ossification, reduced fetal and placental weights at maternally toxic 800 mg/kg
“Delayed ossification-reduced fetal weights and reduced placental weights were observed at 800 mg/kg in the presence of maternal toxicity (reduced maternal body weights).”
✓ VerifiedFDA multi-discipline review, p. 58Source ↗
Safety pharmacology
hERG: sulfone metabolite reduced current by 33% at 9.3 µg/mL
“(hERG) assay showed that fexinidazole sulfone, the fexinidazole metabolite, reduced the residual current by 33 % at 9.3 µg/mL.”
✓ VerifiedFDA multi-discipline review, p. 57Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative